🧴 Melanoma Immunotherapy Response

PD-1/PD-L1 — How Melanoma Hijacks an Immune Brake to Evade Attack

T-cells rely on inhibitory "checkpoint" receptors like PD-1 to prevent excessive, self-damaging immune activity once an infection or threat has been dealt with. Many melanomas co-opt this natural safety mechanism: by expressing PD-L1 on their surface, tumor cells engage PD-1 on tumor-infiltrating T-cells, delivering an inhibitory signal that dampens T-cell proliferation, cytokine production, and cytotoxic killing — allowing the tumor to persist despite being visible to the immune system.

• 1992: PD-1 discovery (Honjo lab; Nobel Prize 2018)
• 40–50%: Melanoma PD-L1 positivity (of tumors by IHC)
• Exhausted T-cells: PD-1 expressed on (chronic antigen exposure)
• T-cell anergy: Checkpoint effect (reduced proliferation & killing)

The PD-1/PD-L1 axis as a tumor immune-evasion mechanism

PD-1 (programmed cell death protein 1) is an inhibitory receptor expressed on activated and exhausted T-cells. Its ligands, PD-L1 and PD-L2, are expressed on antigen-presenting cells and — critically for cancer — upregulated on many tumor cells, including melanoma.

Mechanism of suppression: • PD-L1 on the melanoma cell binds PD-1 on the T-cell surface • Engagement recruits phosphatases (SHP-2) to the T-cell receptor complex • Downstream signaling (PI3K/AKT, Ras/MAPK) is dampened • Result: reduced T-cell proliferation, cytokine secretion (IFN-γ, IL-2), and cytotoxic granule release

Why melanoma is particularly reliant on this pathway: • Melanoma carries one of the highest tumor mutational burdens of any cancer, generating abundant neoantigens • High neoantigen load normally invites strong T-cell infiltration • Upregulating PD-L1 (often via IFN-γ feedback from the very T-cells attacking it, or via oncogenic signaling such as PTEN loss) lets the tumor "turn off" T-cells that have already found it • This adaptive resistance explains why melanoma is exceptionally responsive to checkpoint blockade compared to lower-mutational-burden cancers

Anti-PD-1 Antibodies — Releasing the Brake and Restoring T-cell Function

Monoclonal antibodies such as pembrolizumab and nivolumab bind PD-1 directly on the T-cell surface, sterically blocking its interaction with PD-L1/PD-L2 on tumor cells. With the inhibitory signal removed, previously suppressed tumor-infiltrating lymphocytes regain proliferative capacity, cytokine output, and cytotoxic function — effectively "releasing the brake" on an immune response that was already primed to recognize the tumor.

• 2014: FDA approval (melanoma) (pembrolizumab & nivolumab)
• ~40%: Objective response rate (anti-PD-1 monotherapy, advanced melanoma)
• ~2–4 mo: Median time to response (first significant tumor change)
• ~52%: 5-yr survival (combo) (nivolumab + ipilimumab, CheckMate 067)

Pharmacology of checkpoint blockade and downstream immune reactivation

Anti-PD-1 antibodies are engineered as IgG4 monoclonals (reduced Fc-effector function so they do not deplete the T-cells they bind) that occupy the PD-1 ectodomain, preventing PD-L1/PD-L2 engagement.

Consequences of blockade: • Restored TCR signal transduction downstream of antigen recognition • Increased clonal expansion of tumor-reactive T-cell populations • Renewed IFN-γ and granzyme/perforin production • Re-invigoration is measurable in peripheral blood (Ki-67+ PD-1+ CD8 T-cells) within 2–3 weeks of the first dose

Why the response can look "biphasic" on imaging: • Newly reinvigorated T-cells do not simply sit at the tumor margin — they actively traffic into the tumor mass • This influx of immune cells, edema, and associated inflammation adds volume that standard imaging cannot yet distinguish from proliferating tumor • This sets up the pseudoprogression phenomenon explored in the next stage

Immune Infiltration and Apparent Tumor Growth — The Pseudoprogression Phenomenon

As reactivated T-cells, along with macrophages and other immune cells, flood into the tumor microenvironment, the lesion can transiently enlarge on CT or MRI — not because the tumor is growing, but because it is being infiltrated and inflamed. This apparent progression, occurring in a minority of patients early in treatment, is termed pseudoprogression and can be mistaken for treatment failure if imaging is interpreted with conventional (chemotherapy-era) response criteria.

• ~5–10%: Pseudoprogression incidence (of anti-PD-1-treated melanoma patients)
• First 12 wks: Typical onset (of therapy)
• T-cell/macrophage influx: Underlying drivers (+ edema, necrosis)
• Premature discontinuation: Risk if misread (of an effective therapy)

Why immune infiltration mimics radiographic tumor growth

On cross-sectional imaging, a "tumor" is simply a region of altered tissue density/signal relative to surrounding structures. Standard response criteria (WHO, RECIST) were designed for cytotoxic chemotherapy, where an increase in lesion size reliably indicates viable, proliferating tumor.

With immunotherapy, several biological processes can increase measured lesion size without genuine tumor growth: • Dense infiltration by CD8+ T-cells, CD4+ T-cells, and macrophages • Local edema and vascular permeability changes from cytokine release (IFN-γ, TNF-α) • Areas of immune-mediated necrosis within the lesion • Occasionally, new small lesions appear that represent immune cell aggregates at previously sub-clinical micrometastatic sites, rather than new tumor deposits

Because conventional criteria count any size increase — or any new lesion — as progressive disease, applying them naively during the pseudoprogression window can lead to a therapy being stopped even though it is actively working.

Pseudoprogression versus True Progression — What Continued Monitoring Reveals

Because a single imaging snapshot cannot reliably separate immune infiltration from genuine tumor growth, the key discriminator is the trajectory over time. Pseudoprogression is characteristically followed by stabilization and then measurable shrinkage on subsequent scans, whereas true progressive disease continues to enlarge, develop new lesions, or cause clinical deterioration.

• 4–8 wks: Confirmatory interval (after the initial apparent-progression scan)
• Subsequent shrinkage: Pseudoprogression outcome (on repeat imaging)
• Continued growth: True progression outcome (or new/enlarging lesions)
• High: Clinical status weight (stable/improving symptoms support continuing therapy)

Longitudinal patterns that separate pseudoprogression from true failure

The distinguishing signal is not the first scan showing apparent growth — it is what happens next:

Suggestive of pseudoprogression: • Apparent increase occurs early (commonly within the first 12 weeks) • Patient remains clinically stable or is improving symptomatically • Follow-up imaging 4–8 weeks later shows stabilization or shrinkage of the same lesions • Biopsy, when performed, shows dense lymphocytic infiltrate with limited viable tumor

Suggestive of true progression: • Continued unambiguous enlargement across sequential scans • Development of new lesions in a pattern consistent with metastatic spread • Clinical deterioration (worsening performance status, new symptoms) accompanying the imaging change • No reversal of the growth trend on confirmatory imaging

Because distinguishing the two categories with certainty is impossible from one image alone, guidelines built specifically for immunotherapy response now formalize a "wait and confirm" approach rather than declaring failure at first apparent growth.

iRECIST and Immune-Related Response Criteria — Building Pseudoprogression into the Rulebook

Recognizing that conventional response criteria misclassify a meaningful subset of responding patients as progressors, oncology adopted modified frameworks — immune-related response criteria (irRC) and later iRECIST — that explicitly allow continued treatment through an initial apparent progression event when pseudoprogression is clinically suspected, contingent on confirmatory imaging before progression is finalized.

• 2009: irRC introduced (Wolchok et al., ipilimumab trials)
• 2017: iRECIST published (RECIST working group, Lancet Oncology)
• iUPD → iCPD: Key iRECIST term (unconfirmed → confirmed progression)
• 4–8 wks: Confirmation window (before iUPD becomes iCPD)

How iRECIST operationalizes confirmatory imaging

iRECIST introduces an intermediate category, "unconfirmed progressive disease" (iUPD), that is not immediately treated as a treatment failure:

Workflow: 1. Baseline imaging establishes target and non-target lesions, as in standard RECIST 2. If a scan meets size/new-lesion criteria for progression, it is labeled iUPD rather than confirmed progressive disease 3. Provided the patient is clinically stable, therapy is continued and a confirmatory scan is scheduled, typically 4–8 weeks later 4. If the confirmatory scan shows further growth beyond the iUPD threshold, the case is reclassified as iCPD (confirmed progressive disease) and therapy is generally discontinued 5. If the confirmatory scan instead shows stability or shrinkage, the earlier apparent progression is treated as pseudoprogression, and the patient's best response is reassessed from that point forward

Why this matters clinically: • Prevents premature discontinuation of a therapy that is, in fact, working • Requires clinicians to weigh performance status and symptom trajectory alongside imaging, not imaging alone • Applies specifically to immune checkpoint inhibitors and other immunotherapies where infiltration-driven pseudoprogression is a recognized phenomenon — not to cytotoxic chemotherapy, where growth still reliably indicates treatment failure

The critical clinical safeguard is that continuing therapy through suspected pseudoprogression is only appropriate when the patient is clinically stable or improving. Any sign of true clinical deterioration alongside radiographic growth should prompt reassessment rather than automatic continuation — iRECIST formalizes confirmatory imaging, but does not replace clinical judgment.